Showing results (11-20 of 238) with videos related to
Sort By:
Pageof 24
International Journal of Urology : Official Journal of the Japanese Urological Association|July 10, 2001
Gene and immune therapy for renal cell carcinomaA J Pantuck, A Zisman, A BelldegrunThe Journal of Urology|May 1, 1993
Sensitivity of human renal cell carcinoma lines to TNF, adriamycin, and combination: role of TNF mRNA induction in overcoming resistanceJ T Safrit, A Belldegrun, B BonavidaThe Cancer Journal From Scientific American|February 24, 2000
Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinomaA Belldegrun, O Shvarts, R A FiglinSeminars in Urologic Oncology|November 1, 1996
Renal cell carcinoma: basic biology and clinical behaviorJ R Franklin, R Figlin, A BelldegrunReviews in Urology|September 21, 2006
Immune and genetic therapies for advanced renal cell carcinomaA Zisman, A J Pantuck, A BelldegrunThe Prostate|August 10, 1999
Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesisP J Frost, A Belldegrun, B BonavidaCancer Research|January 1, 1988
Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activityA Belldegrun, L M Muul, S A RosenbergSeminars in Urologic Oncology|November 1, 1996
Immunotherapy and gene therapyB J Gitlitz, A Belldegrun, R A FiglinSeminars in Urology|February 1, 1992
Immunotherapy for renal cell carcinomaA Belldegrun, R Figlin, J Danella, et al.Cellular Immunology|August 25, 1997
Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicityP Frost, C P Ng, A Belldegrun, et al.Pageof 24